Accessibility Menu
Indaptus Therapeutics logo

Indaptus Therapeutics(NASDAQ) INDP

Current Price$2.61
Market Cap$285.37MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-99%
5 Year-99%
1 Year-77%
1 Month-35%
Indaptus Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 2.522026-07-21
Indaptus Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.18%USD 2.632026-07-14
1 month-35.38%USD 3.902026-06-18
3 month-26.74%USD 3.442026-04-22
Year to date-13.4%USD 2.912025-12-31
1 year-76.88%USD 10.902025-07-21
3 year-95.19%USD 52.362023-07-21
5 year-99.39%USD 415.522021-07-22
Since inception-98.99%USD 248.362021-08-04

Indaptus Therapeutics Financials at a Glance

Market Cap

$285.37MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$18.86M

EPS (TTM)

-$16.05

P/E Ratio

-0.16

Dividend

$0.00

Beta (Volatility)

1.29 (Average)

Price

$2.61

Volume

24

Open

$2.52

Previous Close

$2.52

Daily Range

$2.52 - $2.61

52-Week Range

$0.92 - $10.91

Estimated Earnings Date

Aug 17, 2026

INDP News

Foolcom-Featured.png

Indaptus Posts Narrower Loss in Q2

Motley Fool Markets TeamAug 13, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Indaptus Therapeutics

Indaptus develops medicines for cancer and viral infections. Its main product aims to help patients with hard-to-treat tumors or chronic viruses. The company’s work targets people with limited treatment options.

What’s in the Medicine Cabinet?

  • Decoy20 Immunotherapy: Experimental treatment using killed bacteria to stimulate the immune system; targets cancer and viral infections; 0% of revenue (no sales).
  • Oncology Focus: Designed for lymphoma, liver, colon, and pancreatic cancers; aims to help patients with advanced disease.
  • Infectious Disease Targeting: Developed for hepatitis B and HIV; intended for people with chronic viral infections.
  • Combination Therapy: Tested with other drugs, such as checkpoint inhibitors, to boost immune response.
  • Intellectual Property: Holds 61 patents and 17 pending applications; covers technology until at least 2033.

Growth Spurts and Strategic Pivots

  • Changed name from Intec Parent to Indaptus in August 2021.
  • Completed Phase 1 trials for Decoy20 by late 2025; then stopped all clinical development.
  • Received $6 million investment from David E. Lazar in December 2025, leading to new management.
  • Terminated supply agreement with BeOne Medicines in 2025.
  • Now seeking a merger or acquisition with another business as of early 2026.

Why Indaptus Is a Bit Different

Indaptus uses killed bacteria to activate both arms of the immune system, aiming for broader effects than typical immunotherapies. Its technology is protected by patents through at least 2033. The company has no commercial products and is now focused on finding a new business direction.

Five Things You Need to Know

  • No revenue in 2025, 2024, or 2023; all income is from financing.
  • Net loss was $20.8 million in 2025, up 38.8% from 2024.
  • Operating expenses rose 29.1% to $19.8 million in 2025.
  • Cash was $8.5 million at end of 2025, expected to last into Q2 2026.
  • All clinical trials stopped; company is seeking a merger or acquisition.

Bottom Line

Indaptus shifted from drug development to seeking a new business path after stopping clinical trials. The company’s future depends on finding a strategic partner or buyer.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

5

CEO

David Elliot Lazar; Jeffrey A. Meckler

Website

indaptusrx.com

Headquarters

New York City, NY 10019, US

INDP Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-1028.81%

Return on Capital

-629.32%

Return on Assets

-864.69%

Earnings Yield

-6.25%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$285.37MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

113.24M

Volume

24

Avg. Volume

1.01M

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$17.42M

EBITDA

-$18.86M

Operating Cash Flow

-$17.27M

Capital Expenditure

$3.00

Free Cash Flow

-$17.27M

Cash & ST Invst.

$1.50M

Total Debt

$0.00

Indaptus Therapeutics Performance Analysis

Indaptus Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Indaptus Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Indaptus Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -48.54-8.0%
20232023-12-31USD -51.415.9%
20242024-12-31USD -44.96-12.5%
20252025-12-31USD -21.58-52.0%
Indaptus Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-89.6%
Q32025-09-3042.9%
Q42025-12-31-619.2%
Q12026-03-3168.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$285.37MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$57.07M

N/A

Employees

5

N/A

Net Income

-$2.54M

+43.9%

EBITDA

-$2.54M

+43.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$1.50M

-61.5%

Total Debt

$0.00

-100.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

-100.0%

Return on Assets

-8.65%

N/A

Return on Invested Capital

-13.96%

N/A

Free Cash Flow

-$7.01M

-38.9%

Operating Cash Flow

-$7.01M

-38.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NKGNNKGen Biotech, Inc. Common Stock
$0.06+0.00%
SLRXSalarius Pharmaceuticals, Inc.
$0.84+29.23%
REVBRevelation Biosciences, Inc.
$1.12-2.61%
GTBPGT Biopharma, Inc.
$0.34-4.35%

Trending Stocks

Symbol / CompanyPricePrice Chg
ZCMDZhongchao
$9.23+5.28%
ONDSOndas
$8.32+0.09%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.38+0.00%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$35.18+0.00%

Questions About INDP

What is the current price of Indaptus Therapeutics?

Indaptus Therapeutics is trading at $2.61 per share.

What is the 52-week range for Indaptus Therapeutics?

Over the past 52 weeks, Indaptus Therapeutics has traded between $0.92 and $10.91.

How much debt does Indaptus Therapeutics have?

As of the most recent reporting period, Indaptus Therapeutics reported total debt of $0.00.

How much cash does Indaptus Therapeutics have on hand?

Indaptus Therapeutics reported $1.50M in cash and cash equivalents in its most recent financial results.

What is Indaptus Therapeutics’s dividend yield?

Indaptus Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services